Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner

Leukemia

Volumn 30, Issue 2, 2016, Pages 508-513

  He, S ^a   Malik, B ^a   Borkin, D ^a   Miao, H ^a   Shukla, S ^a   Kempinska, K ^a   Purohit, T ^a   Wang, J ^a,c   Chen, L ^a   Parkin, B ^a   Malek, S N ^a   Danet Desnoyers, G ^b   Muntean, A G ^a   Cierpicki, T ^a   Grembecka, J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; EYA1 PROTEIN; HISTONE ACETYLTRANSFERASE; MEIS1 PROTEIN; METHIONINE; MI 2 2; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN; RAS PROTEIN; SIX4 PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA11; TRANSCRIPTION FACTOR HOXA5; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR SIX1; UNCLASSIFIED DRUG; HISTONE LYSINE METHYLTRANSFERASE; MEN1 PROTEIN, HUMAN; MLL PROTEIN, HUMAN; MLL-AF4 FUSION PROTEIN, HUMAN; MLL-AF9 FUSION PROTEIN, HUMAN; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FUSION GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HISTONE METHYLATION; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; LETTER; LEUKEMIA; LEUKEMIA CELL LINE; MIXED LINEAGE LEUKEMIA; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA ANALYSIS; RNA SEQUENCE; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; DRUG EFFECTS; LEUKEMIA, BIPHENOTYPIC, ACUTE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS;

EID: 84959318167     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.144     Document Type: Letter

References (15)

1. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011; 152: 141-154.
2. Cox MC, Panetta P, Lo-Coco F, Del Poeta G, Venditti A, Maurillo L, et al. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am J Clin Pathol 2004; 122: 298-306.
3. Zhang Y, Chen A, Yan XM, Huang G. Disordered epigenetic regulation in MLLrelated leukemia. Int J Hematol 2012; 96: 428-437.
4. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009; 94: 984-993.
5. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 2003; 4: 99-110.
6. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-Associated leukemogenesis. Cell 2005; 123: 207-218.
7. Grembecka J, Belcher AM, Hartley T, Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J Biol Chem 2010; 285: 40690-40698.
8. Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T, et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012; 120: 4461-4469.
9. Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S, et al. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood 2014; 124: 263-272.
10. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
11. Wang QF, Wu G, Mi S, He F, Wu J, Dong J, et al. MLL fusion proteins preferentially regulate a subset of wild-Type MLL target genes in the leukemic genome. Blood 2011; 117: 6895-6905.
12. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20: 66-78.
13. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20: 2147-2154.
14. Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 2015; 27: 589-602.
15. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012; 8: 277-284.